92 related articles for article (PubMed ID: 2578878)
1. Direct and indirect effects of interferon on in vivo murine tumor cell growth.
Uno K; Shimizu S; Ido M; Naito K; Inaba K; Oku T; Kishida T; Muramatsu S
Cancer Res; 1985 Mar; 45(3):1320-7. PubMed ID: 2578878
[TBL] [Abstract][Full Text] [Related]
2. Effect of recombinant human interferon-alpha A/D on in vivo murine tumor cell growth.
Uno K; Shimizu S; Inaba K; Kitaura M; Nakahira K; Kato T; Yamaguchi Y; Muramatsu S
Cancer Res; 1988 May; 48(9):2366-71. PubMed ID: 3356004
[TBL] [Abstract][Full Text] [Related]
3. Effects of recombinant alpha-interferon-gelatin conjugate on in vivo murine tumor cell growth.
Tabata Y; Uno K; Yamaoka T; Ikada Y; Muramatsu S
Cancer Res; 1991 Oct; 51(20):5532-8. PubMed ID: 1833052
[TBL] [Abstract][Full Text] [Related]
4. Treatment regimen and host T-cell-dependent therapeutic effect of interferon in mouse solid tumors.
Kataoka T; Matsuura N; Oh-hashi F; Suhara Y
Cancer Res; 1985 Aug; 45(8):3548-53. PubMed ID: 2410097
[TBL] [Abstract][Full Text] [Related]
5. Environmental conditions favorable for tumor progression in peritoneal cavity induced by peritoneal cells without tumor selectivity.
Segawa K; Ueno Y; Kataoka T
Jpn J Exp Med; 1989 Jun; 59(3):127-33. PubMed ID: 2681889
[TBL] [Abstract][Full Text] [Related]
6. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice.
Mizushima Y; Morikage T; Hirata H; Sato M; Sakamoto K; Yano S
J Biol Response Mod; 1988 Aug; 7(4):371-83. PubMed ID: 3139841
[TBL] [Abstract][Full Text] [Related]
7. Multiple roles of interferon-gamma in the mediation of interleukin 12-induced tumor regression.
Ogawa M; Yu WG; Umehara K; Iwasaki M; Wijesuriya R; Tsujimura T; Kubo T; Fujiwara H; Hamaoka T
Cancer Res; 1998 Jun; 58(11):2426-32. PubMed ID: 9622084
[TBL] [Abstract][Full Text] [Related]
8. IFN-gamma- and cell-to-cell contact-dependent cytotoxicity of allograft-induced macrophages against syngeneic tumor cells and cell lines: an application of allografting to cancer treatment.
Yoshida R; Yoneda Y; Kuriyama M; Kubota T
J Immunol; 1999 Jul; 163(1):148-54. PubMed ID: 10384111
[TBL] [Abstract][Full Text] [Related]
9. Increased in vitro and in vivo tumoricidal activity of a macrophage cell line genetically engineered to express IFN-gamma, IL-4, IL-6, or TNF-alpha.
Nishihara K; Barth RF; Wilkie N; Lang JC; Oda Y; Kikuchi H; Everson MP; Lotze MT
Cancer Gene Ther; 1995 Jun; 2(2):113-24. PubMed ID: 7621259
[TBL] [Abstract][Full Text] [Related]
10. Endogenous accumulation of IFN-gamma in IFN-gamma-R(-/-) mice increases resistance to B16F10-Nex2 murine melanoma: a model for direct IFN-gamma anti-tumor cytotoxicity in vitro and in vivo.
Rodrigues EG; Garofalo AS; Travassos LR
Cytokines Cell Mol Ther; 2002; 7(3):107-16. PubMed ID: 12850810
[TBL] [Abstract][Full Text] [Related]
11. The role of T cells in allografted tumor rejection: IFN-gamma released from T cells is essential for induction of effector macrophages in the rejection site.
Yoneda Y; Yoshida R
J Immunol; 1998 Jun; 160(12):6012-7. PubMed ID: 9637516
[TBL] [Abstract][Full Text] [Related]
12. Relative contribution of antiproliferative and host immunity-associated activity of mouse interferon in murine tumor therapy.
Kataoka T; Oh-hashi F; Sakurai Y; Usuki K; Ida N
Cancer Res; 1984 Dec; 44(12 Pt 1):5661-5. PubMed ID: 6498826
[TBL] [Abstract][Full Text] [Related]
13. In vitro induction of inhibitory macrophage differentiation by granulocyte-macrophage colony-stimulating factor, stem cell factor and interferon-gamma from lineage phenotypes-negative c-kit-positive murine hematopoietic progenitor cells.
Ferret-Bernard S; Saï P; Bach JM
Immunol Lett; 2004 Feb; 91(2-3):221-7. PubMed ID: 15019293
[TBL] [Abstract][Full Text] [Related]
14. [Differential growth inhibition of mycobacteria by interferon-gamma-or tumor necrosis factor-alpha-treated murine peritoneal macrophages].
Sato K; Tomioka H; Saito H
Kekkaku; 1996 Nov; 71(11):607-14. PubMed ID: 8958673
[TBL] [Abstract][Full Text] [Related]
15. Tumoricidal activity of lymphotoxin (tumor necrosis factor beta) in vivo: its effects on macrophages.
Higuchi M; Mitsuno T; Sugimoto M; Okamoto A; Hirose S; Tsukita S; Osawa T
J Biol Response Mod; 1988 Dec; 7(6):619-30. PubMed ID: 3265149
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cell therapy with interferon-alpha synergistically suppresses outgrowth of established tumors in a murine colorectal cancer model.
Ishii S; Hiroishi K; Eguchi J; Hiraide A; Imawari M
Gene Ther; 2006 Jan; 13(1):78-87. PubMed ID: 16107857
[TBL] [Abstract][Full Text] [Related]
17. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2.
Alleva DG; Burger CJ; Elgert KD
J Immunol; 1994 Aug; 153(4):1674-86. PubMed ID: 8046239
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
Hillman GG; Younes E; Visscher D; Hamzavi F; Kim S; Lam JS; Montecillo EJ; Ali E; Pontes JE; Puri RK; Haas GP
Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566
[TBL] [Abstract][Full Text] [Related]
19. Modulation of immune effector cell cytolytic activity and tumour growth inhibition in vivo by Ukrain (NSC 631570).
Liepins A; Nowicky JW
Drugs Exp Clin Res; 1996; 22(3-5):103-13. PubMed ID: 8899312
[TBL] [Abstract][Full Text] [Related]
20. Contrasting effects of activated and nonactivated macrophages and macrophages from tumor-bearing mice on tumor growth in vivo.
Gabizon A; Leibovich SJ; Goldman R
J Natl Cancer Inst; 1980 Nov; 65(5):913-20. PubMed ID: 6933261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
